More than two years after acquiring Tarus Therapeutics, Portage Biotech is relaunching Tarus’ adenosine receptor antagonists in a standalone company helmed by a familiar leader. The offshoot, to be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results